TRACT Therapeutics
Company Details
Status: Private
Employees: 1-10
Location:
Chicago, Illinois, United States
Type:
sample
Technology:
sample
sample
About: TRACT Therapeutics, Inc. has developed a novel approach for restoring immune balance in patients receiving a solid organ transplant or in patients suffering from an autoimmune disease. This therapeutic approach may potentially reduce the chance of organ rejection following a transplant or transfer a patient suffering from an autoimmune disease into a state of remission. The proprietary technology is based on a platform which can be utilized to treat solid organ transplant patients, as well as a number of autoimmune disorders such as Crohn’s Disease. For organ transplant, it shows great promise in preventing rejection of a donated organ, thereby, reducing the need for a second transplant. Over the next few years, TRACT’s TregCel™ personalized therapy could transform the medical approach in transplant medicine by dramatically reducing or eliminating the lifelong use of toxic anti-rejection drugs.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
TRACT Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.